Tirzepatide Side Effects: What the SURMOUNT and SURPASS Trials Reported

Tirzepatide is the dual GIP/GLP-1 receptor agonist behind Mounjaro and Zepbound, and it produced some of the largest mean weight-loss figures reported for an FDA-approved compound. ^[1] Efficacy, though, is only half of what a research buyer or prospective patient needs. This article covers the other half: what side effects the SURMOUNT and SURPASS trial programs actually reported, the mechanism behind why they happen, when they peak, how the trials managed them, and the less common but more serious warnings worth knowing.

A note on how to read this: side-effect incidence figures are trial-specific and depend on dose, population, and titration schedule. Rather than treat any single percentage as a personal prediction, this piece describes the reported patterns (which effects, how frequent relative to each other, and when in the course they cluster) and attributes each to its source.

What are tirzepatide's side effects?

The anchor trial for tirzepatide's obesity indication is SURMOUNT-1, a 72-week Phase 3 trial published in the New England Journal of Medicine in 2022, which enrolled adults with obesity or overweight and at least one weight-related condition. ^[1] Its safety top-line was that the most frequently reported adverse events were gastrointestinal (nausea, diarrhea, constipation, and vomiting), and these were dose-dependent, mostly mild to moderate in severity, and occurred primarily during the dose-escalation period. ^[1] The earlier SURPASS program, which studied tirzepatide in type 2 diabetes and supported the drug's original approval as Mounjaro, reported the same broad pattern. ^[3]

Two framing points matter before the detail. First, the dominant effects are on-target: they are the digestible consequence of the same receptor activity that produces the weight loss and the glycemic benefit, not an unrelated toxicity. Second, the trial reported the GI cluster as concentrated in the dose-escalation window rather than sustained at high rates across the full 72 weeks. Both points come directly from how the trial characterized its adverse events. ^[1]

GI side effects: nausea, diarrhea, constipation, and vomiting, and why they happen

The gastrointestinal effects are the headline of tirzepatide's tolerability profile, and they are not incidental: they are a direct extension of the mechanism. Tirzepatide activates GIP and GLP-1 receptors together, and the GLP-1 component slows gastric emptying, the rate at which the stomach passes its contents to the small intestine. That slowing is part of how the compound reduces appetite, since food stays in the stomach longer, satiety signals persist, and intake falls. ^[2] The same slowing, when exposure rises faster than the gut adapts, is what produces nausea, and often the diarrhea or constipation that come with a shifting digestive tempo.

This is why the effects are reported as dose-dependent rather than all-or-nothing: a larger dose means more receptor activation, more slowing, and a greater chance the gut is pushed past its current tolerance. It also explains the specific complaints people search for, including tirzepatide nausea, tirzepatide diarrhea, tirzepatide constipation, and tirzepatide heartburn. Delayed gastric emptying can push in either direction on stool consistency and can promote reflux-type sensations, all from the same root cause: a digestive system running at a deliberately slowed pace while it recalibrates. Constipation in particular was reported by some participants as more persistent than nausea, likely because slowed transit does not resolve as quickly as the acute nausea response does once a dose step is tolerated.

The practical implication in the trial data is that GI effects were worst when exposure was changing fastest, during the escalation weeks, which is the reason the program built the dose up in steps rather than starting at a target dose. ^[1] None of that is dosing advice; it is the trial-reported rationale for why the escalation schedule is shaped the way it is.

Why the side effects fade

The single most useful thing to understand about tirzepatide's GI effects is why they are concentrated early and ease later. The answer is pharmacokinetics.

Tirzepatide has an elimination half-life of approximately five days, which supports once-weekly dosing but also means plasma levels build gradually and reach steady state in roughly four to five weeks after any dose change. ^[4] During that ramp, exposure is rising, and rising exposure is exactly the condition that provokes GI effects. Once a dose is held and plasma levels plateau, exposure stops climbing, the gut finishes adapting at that level, and the effects tend to settle.

Layered on top of the natural steady-state ramp is titration, the trial's deliberate practice of stepping the dose up over weeks (typically starting at 2.5 mg and increasing in 2.5 mg increments) rather than starting at the target dose. ^[1] Each step gives the system a defined window to adapt before the next increase, which is the reported lever for keeping tolerability manageable. Put together, the two explain the shape people report: a bumpy escalation, then a calmer plateau. In the trial's framing, the side effects were the price of the ramp, not a permanent feature of the compound.

How common is tirzepatide nausea? The trial incidence

Nausea led the adverse-event list across tirzepatide's dose groups in SURMOUNT-1, reported in a dose-dependent way, rising with each higher maintenance dose studied (5 mg, 10 mg, and 15 mg). ^[1] Diarrhea and constipation were each common and similarly dose-related, while vomiting was reported less frequently than nausea. ^[1] The large majority of these events were characterized in the trial as mild to moderate in severity. ^[1]

Discontinuation due to adverse events is the figure that best captures real-world tolerability burden, because it reflects effects severe enough that a participant stopped the drug entirely. In SURMOUNT-1, treatment discontinuation attributable to adverse events occurred in roughly the 4 to 7% range across the tirzepatide dose groups over 72 weeks, compared with a lower rate on placebo, and gastrointestinal events were the leading cause. ^[1] That figure is useful context: even though a majority of participants experienced some GI symptom during the trial, the overwhelming majority did not find it severe enough to stop.

How tirzepatide's side effects were managed in the trials

The trial's answer to tolerability was structural, not reactive: gradual dose titration. The clinical program escalated the dose stepwise over several weeks rather than starting at the target dose, and this is the mechanism most directly credited with keeping the GI effects manageable. ^[1] Titration works because of the multi-day half-life: each step's exposure layers onto the last, so the body adapts to a slowly rising level rather than a sudden jump. ^[4]

It is worth stating plainly what this section is and is not. Describing the trial's titration schedule is a description of study design, not an instruction to titrate a particular way, on a particular schedule, at a particular dose. Those are clinical decisions made under a prescriber's supervision, outside the scope of this article. The value here is understanding why the escalation exists: it is the trade the program made to buy tolerability while exposure climbed to a level where the efficacy showed up.

Less common but more serious: gallbladder disease

Beyond the GI cluster that dominates day-to-day tolerability, the trial program reported gallbladder-related events, including cholelithiasis (gallstones) and cholecystitis (gallbladder inflammation), at a higher rate on tirzepatide than on placebo. ^[1] This is not characterized as a direct toxic effect on the gallbladder so much as a consequence of the pattern reported across rapid-weight-loss interventions generally: fast, substantial weight loss is an independent, well-documented risk factor for gallstone formation, regardless of the method used to achieve it. Because tirzepatide can drive weight down quickly, that same rapid-loss risk factor is plausibly in play alongside any direct pharmacologic contribution, and the trial literature does not fully separate the two.

The practical takeaway is a symptom pattern to know, not a personal risk score: persistent pain in the upper right abdomen, fever, or yellowing of the skin or eyes (jaundice) are reasons to seek prompt medical evaluation rather than assume the discomfort is routine GI tolerability. ^[1]

Less common but more serious: acute pancreatitis

Acute pancreatitis, inflammation of the pancreas, was reported in a small number of participants across the tirzepatide trial program and is a recognized, labeled warning for the GLP-1/GIP receptor-agonist class generally, not unique to tirzepatide. ^{[1] [3]} The rate reported across the program was low, and a causal relationship between the drug and pancreatitis has not been definitively established, but the signal is taken seriously enough that it appears in prescribing information for the approved product.

The classic presentation to know is severe, persistent abdominal pain, often radiating to the back, frequently accompanied by nausea and vomiting that does not resemble the routine, transient nausea of ordinary GI tolerability. ^[1] This is general safety framing describing a labeled warning, not a diagnosis or an individual risk assessment. Any severe or persistent abdominal pain warrants prompt medical evaluation.

Injection-site reactions and other reported effects

Injection-site reactions, including redness, itching, or mild swelling at the injection site, were reported in the trial program, generally described as mild and uncommon relative to the GI cluster. ^[1] The trial program also reported a modest increase in heart rate, a recognized, class-typical observation for GLP-1 receptor agonists generally, alongside favorable changes in several cardiometabolic markers that accompanied the weight loss. ^[1] These are reported here as trial and class context, not as an individual risk assessment.

Hair shedding is a commonly searched concern across the entire weight-loss field, including tirzepatide, semaglutide, and rapid weight loss by any means. The leading explanation invoked across the field is telogen effluvium, a temporary, stress-related shift in the hair growth cycle triggered by rapid weight loss and the nutritional changes that accompany a sharp drop in intake, rather than a direct toxic effect of the drug on hair follicles. This framing should be confirmed by a clinician, since it is not characterized in the tirzepatide trial literature as a primary, direct adverse effect in the way the GI events are.

Does tirzepatide cause more side effects than semaglutide?

Because tirzepatide activates both GIP and GLP-1 receptors while semaglutide activates GLP-1 alone, a natural question is whether the added receptor changes the tolerability profile. The honest answer starts with a caveat: the two compounds have not been extensively compared head-to-head for tolerability at matched doses, so most of what follows is drawn from separate trials with different populations and titration schedules.

What those separate trials show is broad class similarity. In semaglutide's STEP program and tirzepatide's SURMOUNT and SURPASS programs, the most common adverse events were gastrointestinal, with nausea leading the list in both, and were dose-dependent, mostly mild to moderate, and concentrated early. ^{[5] [1]} Some analyses have suggested tirzepatide's added GIP activity may soften the GI burden somewhat relative to GLP-1 alone, since GIP signaling is theorized to counteract some GLP-1-driven nausea in animal models, but this remains an active area of research rather than a settled comparative finding, and cross-trial rate comparisons are confounded by different doses and populations. The defensible statement is narrower: the GI profile is a class property, driven substantially by the shared GLP-1 mechanism, and it is managed the same way across both compounds, gradual titration timed to each drug's pharmacokinetics.

How the side-effect timeline relates to when tirzepatide starts working

A related troubleshooting search, tirzepatide not working or why am I not losing weight, usually describes the same early weeks that produce the GI effects, and the pharmacology offers a clean explanation that ties the two together. Weight-loss and glycemic effects in the trials were dose-dependent, and plasma levels take roughly four to five weeks to reach steady state after any dose change. ^{[1] [4]} That means the early, low-dose weeks, the same weeks when GI effects are most likely, are also the weeks when the metabolic effect is weakest, because exposure has not yet built to the level where the trial measured its results. Reading the first few weeks as the verdict is a common misread; the trial's primary endpoints were measured at 72 weeks for exactly this reason.

Putting the side-effect profile in context

Tirzepatide's tolerability profile reads as a coherent whole once the mechanism is in view. The dominant effects are gastrointestinal and on-target: the digestible cost of slowed gastric emptying, the same process that drives appetite reduction. They are dose-dependent and concentrated in the escalation window, easing as exposure plateaus, and only a modest share of participants discontinued because of them. ^[1] Less common but more serious signals, gallbladder disease and acute pancreatitis, are recognized class-level concerns worth knowing even though they affect a small minority. The whole profile was managed in the trials through gradual titration timed to the compound's roughly five-day half-life.

For a research or clinical decision, the useful takeaway is that the side-effect timeline and the efficacy timeline are the same timeline, both governed by how exposure builds toward steady state. Understanding that one curve explains both why the early weeks feel bumpy and why they understate the compound's eventual effect.

For research and educational purposes only. Not medical advice. Side-effect patterns and incidence figures describe findings from published clinical trials and FDA labeling information; they are not predictions, instructions, or management advice for any individual. FDA-approved tirzepatide (Mounjaro, Zepbound) is available only by prescription and under clinician supervision. Research-labeled tirzepatide is not approved for human use.